Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Rocket Pharmaceuticals (RCKT) Receivables - Net (2020 - 2023)

Rocket Pharmaceuticals (RCKT) has disclosed Receivables - Net for 4 consecutive years, with $50000.0 as the latest value for Q4 2023.

  • Quarterly Receivables - Net changed N/A to $50000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $50000.0 through Dec 2023, changed N/A year-over-year, with the annual reading at $50000.0 for FY2023, N/A changed from the prior year.
  • Receivables - Net hit $50000.0 in Q4 2023 for Rocket Pharmaceuticals, down from $900000.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $1.6 million in Q2 2020 to a low of $50000.0 in Q4 2023.
  • Historically, Receivables - Net has averaged $835714.3 across 4 years, with a median of $1.0 million in 2021.
  • Biggest five-year swings in Receivables - Net: plummeted 37.5% in 2021 and later skyrocketed 800.0% in 2022.
  • Year by year, Receivables - Net stood at $1.1 million in 2020, then dropped by 9.09% to $1.0 million in 2021, then decreased by 10.0% to $900000.0 in 2022, then crashed by 94.44% to $50000.0 in 2023.
  • Business Quant data shows Receivables - Net for RCKT at $50000.0 in Q4 2023, $900000.0 in Q1 2022, and $1.0 million in Q2 2021.